Skip to main content
. 2018 Mar 8;9(20):15208–15218. doi: 10.18632/oncotarget.24622

Figure 2. Overall survival rate.

Figure 2

(A) Relationship between Overall survival and histological response in advanced gastric cancer patients who were underwent docetaxel and cisplatin combination preoperative chemotherapy. (B) Relationship between Overall survival and RPN2 expression in advanced gastric cancer patients who were underwent docetaxel and cisplatin combination preoperative chemotherapy. (C) Relationship between Overall survival and RPN2 expression in clinical Stage II-III patients who were underwent docetaxel and cisplatin combination preoperative chemotherapy. (D) Relationship between Overall survival and RPN2 expression in clinical Stage IV patients who were underwent docetaxel and cisplatin combination preoperative chemotherapy.